Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Respiratory Safety of Lemborexant in Adult and Elderly Healthy Subjects and Adult and Elderly Subjects With Mild Obstructive Sleep Apnea
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Jun 2023
Price :
$35
*
At a glance
- Drugs Lemborexant (Primary)
- Indications Sleep apnoea syndrome
- Focus Adverse reactions; Pharmacodynamics
- Acronyms Study 102
- Sponsors Eisai Inc
- 06 Jun 2023 According to a Eisai Co Ltd media release, data from this study will be presented at the 37th annual meeting of the Associated Professional Sleep Societies (SLEEP 2023), to be held from June 3-7, 2023 in Indianapolis, IN, the United States.
- 16 Mar 2021 Results (n=17) from part 1 of the study published in the Clinical Drug Investigation
- 11 Jun 2019 According to an Eisai Inc media release, results from the study were presented at the 33rd annual meeting of the Associated Professional Sleep Societies (SLEEP 2019).